Abstract This article succinctly summarizes the available evidence on the risk of bone fractures with sodium-glucose co-transporter-2 inhibitors. The US Food and Drug Administration has strengthened the warning for canagliflozin related to the increased risk of bone fractures, and added new information about decreased bone mineral density. The agency has also said that it will evaluate the risk of bone fractures with other drugs in the sodium-glucose co-transporter-2 inhibitor class. Increases in parathyroid hormone levels and decreases in 1,25-dihydroxyvitamin D levels have been postulated as possible mechanisms. In contrast, some studies with dapagliflozin have shown no effects on bone health. Because a consensus has not been reached, we believe that an expert opinion on how to interpret the available evidence would be of great benefit for clinicians.
Introduction
In October 2015, the US Food and Drug Administration (FDA) issued a warning on a possible risk of bone fractures associated with the use of the sodium-glucose co-transporter-2 (SGLT-2) inhibitor canagliflozin [1] . The warning was based on two observations:
1. A pooled analysis of data from nine trials, including an interim analysis of the CANagliflozin cardioVascular Assessment Study (CANVAS) and eight smaller phase III trials, showing a significant increase in the incidence of adjudicated fractures with canagliflozin. This increase was largely driven by the interim results of CANVAS, with no clear signal of risk in the non-CANVAS trials [2] .
2. A 104-week, double-blind, placebo-controlled trial showing a small, but statistically significant, reduction in hip bone mineral density associated with canagliflozin, with no effects on bone density on other sites [3] .
This warning raised important questions on the possibility of detrimental effects of canagliflozin, and of other molecules of the class, on bone metabolism. This article briefly reviews experimental data and clinical evidence on the issue.
SGLT-Inhibitors and Bone Metabolism:
Mechanistic and Experimental Studies
The potential mechanisms through which canagliflozin (or other SGLT-2 inhibitors) could augment the risk of fractures are not completely clear. An increase in the incidence of bone fractures can be due either to a higher incidence of falls or to an impoverishment of bone mechanical quality. It is possible that treatment with canagliflozin, or any other SGLT-2 inhibitor, determines an increased risk of falls: when added to sulfonylureas or insulin, SGLT-2 inhibitors may induce an increased risk of hypoglycemia, which, in turn, is associated with falls; furthermore, symptoms related to volume depletion (particularly hypotension) can increase the risk of falls. Unfortunately, we have no data from clinical trials on the incidence of falls associated with canagliflozin or other SGLT-2 inhibitors. Interestingly, the increase in fracture risk with canagliflozin was apparent within 12-26 weeks of treatment, when the decline in bone density appears to be insufficient to represent a plausible mechanism [4] . There is some available information on the effects of SGLT-2 inhibitors on bone metabolism. In a double-blind, placebo-controlled, 2-year trial on over 700 patients with type 2 diabetes mellitus, canagliflozin induced a significant reduction in bone mineral density (BMD) measured at the hips, but not in other anatomical sites [3] . A smaller and shorter term placebo-controlled trial failed to detect any significant effect of dapagliflozin on hip BMD; however, patients treated with dapagliflozin showed, on average, a greater loss of femoral neck BMD than those receiving the placebo, although the difference failed to reach statistical significance [5] . Based on these results, a larger scale trial with a longer follow-up is needed to rule out any detrimental effect of dapagliflozin on bone density. No data on BMD during treatment with empagliflozin, ertugliflozin, or other SGLT-2 inhibitors are available to date. Notably, SGLT-2 inhibitors induce weight loss, which is associated per se with a reduction in BMD [6] .
To date, there is no evidence that SGLT-2 is expressed in the bone. However, the inhibition of SGLT-2 could affect bone metabolism indirectly, modulating calcium/ phosphate homeostasis. There is evidence from animal studies that the inhibition of SGLT-2 increases tubular reabsorption of phosphate, leading to increased serum phosphate levels capable of stimulating parathyroid hormone secretion [7] . In a pooled analysis of phase III clinical trials with canagliflozin, a small increase of serum phosphate was observed [8] ; similar findings were reported for dapagliflozin [9] , particularly in patients with chronic kidney disease [10] . A small increase in phosphorus levels was also observed in some phase III studies with empagliflozin [11] , but not in the larger EMPA-REG OUT-COME trial [12] . A small increase in parathyroid hormone levels was reported with dapagliflozin [9, 10] , but not with canagliflozin [4] , whereas for empagliflozin no change was detected in phase II-III studies [11] , but a small increase was observed in the EMPA-REG OUTCOME trial [12] . Conversely, although an increase in urinary calcium excretion with SGLT-2 inhibitors occurred in pre-clinical studies in rodents [4, 9, 11] , in clinical trials, a trend toward an increase was reported with dapagliflozin [8] , but not with other SGLT-2 inhibitors [4, 11, 12] . Serum calcium levels were generally unchanged in clinical trials with SGLT-2 inhibitors [4, 9, 11, 12] . A trend toward a reduction in 1,25-dihydroxy-vitamin D, observed in experimental studies in rodents [4] , was reported in early trials with empagliflozin [11] , but not with other SGLT-2 inhibitors [4, 9] .
SGLT-2 inhibitors also have a weak inhibitory activity on SGLT-1. The inhibition of this latter transporter, in rodents, determined intestinal carbohydrate malabsorption, which is accompanied by an enhancement of calcium absorption, a reduction in parathyroid hormone and 1,25-dihydroxy-vitamin D, hyperostosis, and hypercalciuria [13] . It is possible that SGLT-2 inhibitors interfere with calcium metabolism via their action on SGLT-1; however, the affinity of those molecules for SGLT-1 is very low, with the possible exception of canagliflozin [14] . A further peculiarity of canagliflozin is its effect on estradiol levels, which were decreased in a dose-dependent fashion in clinical trials [3, 4] . The mechanisms underlying this phenomenon, which could contribute to the reduction in bone density, are unclear. Unfortunately, no data are available on the effect of other SGLT-2 inhibitors on estradiol.
SGLT-2 Inhibitors and Bone Fractures:
Evidence from Clinical Trials
The pooled analysis showing an increased risk of fractures with canagliflozin [2] , which prompted the FDA warning [1] , was driven by the interim results of CANVAS, a cardiovascular safety trial, which enrolled patients with prior cardiovascular events or multiple cardiovascular risk factors. In the corresponding cardiovascular safety trial with empagliflozin, the EMPA-REG OUTCOME trial, enrolling patients with similar characteristics, and with a similar incidence of fractures in the placebo group, the active drug was not associated with any increase in fracture risk [12] . The analysis of those two cardiovascular outcome trials suggests that canagliflozin could have a specific effect on the risk of bone fractures, which is not present with other molecules of the class. However, in a placebocontrolled trial on patients with chronic kidney disease, a trend toward an increased incidence of bone fractures was observed also with dapagliflozin [10] . A thorough analysis of events of bone fractures recorded in smaller phase II-III trials with SGLT-2 inhibitors can add some further information on this issue. A recent metaanalysis, which included also data from the cardiovascular outcome studies cited above, did not detect any increase in the risk of bone fractures associated with SGLT-2 inhibitors [14] . Further data can be obtained from the medical reviews of approved FDA drugs, which are summarized in Table 1 [4, 9, 11] , and which collect all trials submitted for drug registration. No trend toward an increase of fracture risk was reported for empagliflozin and dapagliflozin, although for the latter molecule a signal of risk was detected in a specific population, i.e., those with abnormal renal function [9, 10] . Conversely, the incidence of bone fractures appeared to be higher with canagliflozin than with its comparators [4] . However, the dataset used for FDA drug assessment of canagliflozin included a preliminary interim analysis of CANVAS, whereas cardiovascular outcome trials were not part of the regulatory submissions for dapagliflozin and empagliflozin, which included only phase II and III trials with metabolic endpoints. Therefore, data obtained with different molecules are not directly comparable.
Patients included in cardiovascular outcome trials differ from those of earlier studies (e.g., they show a higher age and duration of diabetes, a greater number of co-morbidities and concurrent therapies, and a higher frequency of cardiovascular and microvascular disease); these differences could modulate the effect of SGLT-2 inhibitors on bone metabolism. In fact, when excluding CANVAS, the risk of fractures with canagliflozin does not seem different from that of the other molecules of the class. However, the duration of trials with non-cardiovascular endpoints could be too small to detect any safety issue related to the reduction of bone density. Furthermore, the cardiovascular outcome study with empagliflozin, which enrolled patients similar to those of CANVAS, did not reveal any increase of bone fractures, suggesting that such issue could be specific of canagliflozin (Table 1) . Notably, the actual incidence of fractures in the control group of the EMPA-REG OUT-COME trial was higher than that of the placebo arm in CANVAS, despite similar patient characteristics (Table 1) ; this could have contributed to the apparent differences in drug effects. Ongoing cardiovascular safety trials with other molecules of the class will provide further information in the next 2-3 years.
Conclusions: Bone Fractures and Clinical Use of SGLT-2 Inhibitors
Safety is an essential component in the evaluation of the risk/benefit ratio, which should drive our clinical decisions. In this context, the issue of bone fractures in patients with type 2 diabetes is relevant. In fact, this disease is associated with an increase in fracture risk [15] , which could be aggravated by pharmacological treatment for diabetes [16, 17] . The assessment of the effect of any drug on fracture risk is problematic because an unfavorable action may become evident only after a prolonged exposure. The possible sources of data in this respect are represented by observational studies and appropriately sized long-term clinical trials. Observational studies are available only for drugs that have already been on the market for several years, and therefore they are of no use for more recent agents, such as SGLT-2 inhibitors. Long-term clinical trials are designed for purposes different from the assessment of the effects on bone metabolism; usually, their principal endpoint is represented by cardiovascular events, including patients at high cardiovascular risk. Consequently, the populations enrolled in those trials are not representative of those actually receiving a prescription for the investigated drug in the real world. Notably, patients in cardiovascular outcome studies are usually older, with a greater number of co-morbidities, and a higher incidence of bone fractures, than those recruited in earlier trials. This is also the case of SGLT-2 inhibitors. Not surprisingly, the signal of risk came from one cardiovascular outcome trial, CANVAS [2] , whereas no apparent increase in the incidence of fractures was present in non-cardiovascular studies with the same molecule. It is possible that the absence of additional risk with canagliflozin in early trials is the result of an insufficient sample size or study duration; however, it is also possible that the discrepancy in results was determined by diversities in the characteristics of the enrolled patients. Notably, no signal of risk was present with empagliflozin, even in the cardiovascular outcome trial [12] , whereas the results of the corresponding large-scale, long-term trial with dapagliflozin [18] are not yet available. Mechanistic studies, such as those on bone density [3, 5] , are interesting, but their interpretation is problematic because of the interference of weight loss. Canagliflozin, and the other SGLT-2 inhibitors, induce a number of small changes in calcium and phosphate metabolism, briefly summarized above, which could theoretically affect bone density; however, the clinical relevance of those modifications remains uncertain.
Based on the limited evidence available to date, treatment with canagliflozin could be associated with an increase in the risk of bone fractures, which is evident only in patients with a higher burden of co-morbidities, such as those enrolled in the cardiovascular outcome trials. Other molecules of the class, such as empagliflozin, appear to be safer in this respect, whereas further data are needed for any judgment on dapagliflozin. This opinion is based on very little evidence: data from the CANVAS trial, which are the basis for the warning on canagliflozin, derive from an interim analysis of limited statistical power. However, the statement on the safety of empagliflozin results from a trial with only 3.1 years of follow-up, which could be inadequate for the detection of long-term safety issues.
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